Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease
Source: Streetwise Reports
November 2, 2017 (Investorideas.com Newswire) An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications.
Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women's health and endocrine diseases. Its lead drug development candidate, Relugolix, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly lowers estrogen and progesterone in women and testosterone levels in men when administered once daily.
In an Oct. 25 research report, H. C. Wainwright analyst Andrew Fein outlined the high points of Biogen Inc.'s (BIIB:NASDAQ) quarterly earnings update, noting that a "buzz" surrounds Spinraza but that his firm maintains its "long-standing focus on the AD [Alzheimer's disease] franchise."
Fein listed four takeaways from the company's quarterly report:
- Multiple sclerosis "remains the main cash source for the company, despite a negative impact from Ocrevus"
- "Strong ex-U.S. adoption" of Spinraza, used to treat spinal muscular atrophy, "drove current quarter-to-quarter growth"
- "Renegotiation of the agreements with Eisai Inc. (ESALF:OTCPK; not rated) and Neurimmune (private), along with Eisai's option-in on aducanumab, signaled Biogen's (and Eisai's) conviction behind the program"
- "Continued advancement and expansion of its neurology pipeline with enhanced ASO and gene therapy manufacturing capabilities form the cornerstone of Biogen's long-term value proposition"
Fein also asserted that his firm elects "to focus on the prospects of the AD franchise with aducanumab as the leading asset based on the view that it is a major long-term value driver." Eisai's opt-in on aducanumab "certainly adds an external validation for the program as well," the analyst added.
Fein commented on Biogen's other Alzheimer's assets as well, asserting, "While investors may remain cautious of aducanumab as the depressed outlook for Abeta thesis remains, largely due to the misses of several high-profile Phase 3 trials by targeting Abeta, we highlight the company's robust AD pipeline. Beyond two anti-Abeta antibodies, namely aducanumab (in Phase 3) and BAN2401 (in Phase 2), the company has assets targeting BACE1 (Elenbecestat) and tau (BIIB092, BIIB076, BIIB080), two of the most promising therapeutic approaches."
Biogen's plans for expanding its reach in neuroscience, including development of therapies for pain and epilepsy, also garnered Fein's attention. "[The expanding] neurology pipeline reaffirms our belief in [the] company's core competence of de-risking," the analyst wrote. "We believe that through the company's improved translational capabilities, the probability of success across neuroscience should be enhanced, and we view these capabilities as the company's ultimate value driver of future growth."
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.